Refine by
Clinical Proof Technology
4 companies found
Technologybased inGeneve, SWITZERLAND
STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have ...
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches ...
Technologybased inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...
Technologybased inPacé, FRANCE
Blueback markets a medical device that makes it easy and quick to assess the tone of the deep muscles. True innovation, Blueback Physio, supports healthcare professionals in this difficult but essential assessment in their ...
As often in entrepreneurship, the idea of BlueBack was born from a personal story. The story of a young woman who at the age of twenty, was forbidden to practice sports because of back pain. After a long medical journey (specialized doctor, ...
Technologybased inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
RTX (resiniferatoxin) is a unique neural intervention molecule that is highly selective and may be applied peripherally (e.g., nerve block, intra-articular) or centrally (e.g., epidural), to control chronic pain across multiple conditions including ...